These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 25976766)

  • 21. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
    Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
    J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.
    Song X; Zhao Z; Qi X; Tang S; Wang Q; Zhu T; Gu Q; Liu M; Li J
    Oncotarget; 2015 Mar; 6(7):5263-74. PubMed ID: 25742791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
    Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
    Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
    Nakashima T; Ishii T; Tagaya H; Seike T; Nakagawa H; Kanda Y; Akinaga S; Soga S; Shiotsu Y
    Clin Cancer Res; 2010 May; 16(10):2792-802. PubMed ID: 20406843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Albendazole inhibits HIF-1α-dependent glycolysis and VEGF expression in non-small cell lung cancer cells.
    Zhou F; Du J; Wang J
    Mol Cell Biochem; 2017 Apr; 428(1-2):171-178. PubMed ID: 28063005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
    Nguyen CT; Ann J; Sahu R; Byun WS; Lee S; Nam G; Park HJ; Park S; Kim YJ; Kim JY; Seo JH; Lee J
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127374. PubMed ID: 32738983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.
    Suda A; Kawasaki K; Komiyama S; Isshiki Y; Yoon DO; Kim SJ; Na YJ; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem; 2014 Jan; 22(2):892-905. PubMed ID: 24369839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 2',4'-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC).
    Seo YH
    Arch Pharm Res; 2015 Oct; 38(10):1783-8. PubMed ID: 25855012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
    Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
    Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
    Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
    Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
    Zismanov V; Drucker L; Gottfried M
    Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
    Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
    Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
    Graham B; Curry J; Smyth T; Fazal L; Feltell R; Harada I; Coyle J; Williams B; Reule M; Angove H; Cross DM; Lyons J; Wallis NG; Thompson NT
    Cancer Sci; 2012 Mar; 103(3):522-7. PubMed ID: 22181674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5,3'-Dihydroxy-6,7,4'-trimethoxyflavanone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells.
    Kim KM; Heo DR; Lee J; Park JS; Baek MG; Yi JM; Kim H; Bang OS
    Chem Biol Interact; 2015 Jan; 225():32-9. PubMed ID: 25446852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy.
    Kim WY; Chang DJ; Hennessy B; Kang HJ; Yoo J; Han SH; Kim YS; Park HJ; Seo SY; Mills G; Kim KW; Hong WK; Suh YG; Lee HY
    Cancer Prev Res (Phila); 2008 Dec; 1(7):577-87. PubMed ID: 19139008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
    Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.